ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1553

An Analysis of Real-World Data on the Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis

Christopher J. Edwards1, Jack F Bukowski2, Sara Burns3, Heather Jones2, Ronald Pedersen2, Katherine Roshak2, Joan M Sopczynski2, Mazhar Thakur4 and Lisa Marshall2, 1University of Southampton, Southampton, United Kingdom, 2Pfizer, Collegeville, PA, 3Pfizer, Cambridge, MA, 4RegSafe Consulting Ltd, Wokingham, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: etanercept, rheumatoid arthritis (RA) and safety

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Both rheumatoid arthritis (RA) and older age are associated with a higher risk of comorbidities, and the appropriate treatment approach for older patients is unclear. We evaluated real-world data (RWD) to determine whether there is an association between etanercept (ETN) and select adverse events (AEs) in patients with RA, stratified by age. We hypothesized that there is no difference in risk of AEs between younger (aged ≤65 yr) and older (aged >65 yr) patients.

Methods: Data from 2013 to 2018 were analyzed from the IBM Watson Health MarketScan Database which contains information on 104.5 million distinct patients, including 531,996 with RA. Patients were required to be enrolled ≥1 yr prior to RA diagnosis; the first exposure to ETN was after RA diagnosis and before the AE of interest: congestive heart failure (CHF), serious infection (SI), non-melanoma skin cancer (NMSC), or interstitial lung disease (ILD). Proportion of patients experiencing each AE was determined for patients ≤65 yr and >65 yr receiving and not receiving ETN. Differences were evaluated using Fisher’s Exact test. Logistic regression models assessed the interaction between ETN and age group. Propensity matching was performed, and logistic regression was applied using the propensity-score-matched cohort. Patients receiving and not receiving ETN were matched by age, age >65 yr, gender, and geographical region.

Results: Average age of patients with RA was 56.1±14.9 yr; 73.5% were female. Risk of experiencing CHF did not differ significantly for patients receiving vs not receiving ETN: odds ratio (OR) = 0.883, 95% CI: 0.770-1.009; p=0.072. However, the risks of SI, NMSC, and ILD were significantly higher in the patients receiving ETN (SI: OR=1.14, 95% CI: 1.07-1.21, p<0.001; NMSC: OR=1.20, 95% CI: 1.05-1.37, p=0.008; and ILD: OR=1.89, 95% CI: 1.56-2.29, p<0.001). In patients >65 yr, the occurrence of CHF was lower for patients receiving vs not receiving ETN (8.7% vs 10.7%, p=0.025) (Figure); the occurrence of SI and NMSC did not differ significantly; SI: 21.8% vs 20.4% for ETN vs no ETN, respectively, p=0.186; NMSC: 6.3% vs 5.2%, p=0.952. The occurrence of ILD was higher for patients receiving ETN: 3.4% vs 1.4%, p<0.001. The difference in AE occurrence between patients ≤65 yr and >65 yr did not differ significantly for patients receiving vs not receiving ETN for any of the AEs (Figure).

Conclusion: In this analysis of RWD of patients with RA, the risk of CHF, SI, NMSC, and ILD between younger and older patients was not modified by ETN usage. This analysis suggests an overall acceptable safety profile of ETN; however, clinicians should use caution when treating older patients.

 

 

 


Figure. Occurrence of AEs according to age group and ETN treatment status

 

 

 


Disclosure: C. J. Edwards, Pfizer, Abbvie, Biogen, UCB, Janssen, Samsung, Mundipharma, Roche, Lilly, Merck, 2,Pfizer, Abbvie, Biogen, UCB, Janssen, Samsung, Mundipharma, Roche, Lilly, Merck, 5,Pfizer, Abbvie, Biogen, UCB, Janssen, Samsung, Mundipharma, Roche, Lilly, Merck, 8; J. F. Bukowski, Pfizer, Inc., 1,Pfizer, Inc., 3; S. Burns, Pfizer, Inc., 1,Pfizer, Inc., 3; H. Jones, Pfizer, Inc., 1,Pfizer, Inc., 3; R. Pedersen, Pfizer, Inc., 1,Pfizer, Inc., 3; K. Roshak, Pfizer, Inc., 3; J. M. Sopczynski, Pfizer, Inc., 1,Pfizer, Inc., 3; M. Thakur, RegSafe Consulting Ltd, 3,RegSafe Consulting Ltd, 4,Pfizer, Inc., 5; L. Marshall, Pfizer, Inc., 1,Pfizer, Inc., 3.

To cite this abstract in AMA style:

Edwards CJ, Bukowski JF, Burns S, Jones H, Pedersen R, Roshak K, Sopczynski JM, Thakur M, Marshall L. An Analysis of Real-World Data on the Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/an-analysis-of-real-world-data-on-the-safety-of-etanercept-in-elderly-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-analysis-of-real-world-data-on-the-safety-of-etanercept-in-elderly-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology